antiamyloidogenic

Antiamyloidogenic refers to the property of substances, interventions, or biological processes that prevent or reduce the formation of amyloid fibrils and plaques, or counteract amyloidogenic pathways. It is commonly used in the context of protein misfolding diseases such as Alzheimer's disease, where amyloid beta and tau aggregates arise, and in type 2 diabetes, where islet amyloid polypeptide forms fibrils, but the term may apply to other amyloidogenic conditions as well.

Mechanisms of antiamyloidogenic action include inhibition of protein misfolding and aggregation, stabilization of native protein structures, disruption of early oligomer formation, and disaggregation of existing fibrils. They can also involve enhancement of cellular clearance through autophagy or the proteasome, as well as strategies to reduce production of amyloid-prone fragments by modulating processing pathways. In addition, molecular chaperones and immune approaches that target amyloid species are explored within this framework.

Examples of antiamyloidogenic approaches studied in research include polyphenols such as epigallocatechin gallate (EGCG), curcumin, and resveratrol, which have been investigated for their effects on aggregation pathways. Other strategies involve metal chelators that mitigate metal-induced aggregation and the use of designed peptides or antibodies that interfere with aggregation or promote clearance. Researchers assess antiamyloidogenic activity using in vitro assays that monitor aggregation kinetics and in vivo models to evaluate safety and efficacy. The term encompasses a broad range of approaches, and translating laboratory findings into clinical benefits remains challenging.